nivolumab
bms
['melanoma', 'bmsnews', 'bms', 'bristol']
#media: announcing positive results from our phase 3 trial evaluating an adjuvant #immunotherapy treatment for completely resected stage iib and iic #melanoma at s smr 2022 congress. 
Patients are our purpose. We come together each day to discover, develop and deliver transformative science to help patients prevail over serious diseases.